Thomas Gajewski to Humans
This is a "connection" page, showing publications Thomas Gajewski has written about Humans.
Connection Strength
1.777
-
PKCd Germline Variants and Genetic Deletion in Mice Augment Antitumor Immunity through Regulation of Myeloid Cells. Cancer Immunol Res. 2025 Apr 02; 13(4):547-559.
Score: 0.029
-
Dendritic cell-intrinsic PTPN22 negatively regulates antitumor immunity and impacts anti-PD-L1 efficacy. J Immunother Cancer. 2024 Oct 26; 12(10).
Score: 0.029
-
Batf3+ DCs and the 4-1BB/4-1BBL axis are required at the effector phase in the tumor microenvironment for PD-1/PD-L1 blockade efficacy. Cell Rep. 2024 05 28; 43(5):114141.
Score: 0.028
-
Tissue-resident memory T cells in immune-related adverse events: friend or foe? Oncoimmunology. 2023; 12(1):2197358.
Score: 0.026
-
Checkpoint Blockade-Induced Dermatitis and Colitis Are Dominated by Tissue-Resident Memory T Cells and Th1/Tc1 Cytokines. Cancer Immunol Res. 2022 10 04; 10(10):1167-1174.
Score: 0.025
-
Insights from a Rapidly Implemented COVID-19 Biobank Using Electronic Consent and Informatics Tools. Biopreserv Biobank. 2023 Apr; 21(2):166-175.
Score: 0.024
-
Wilms tumor reveals DNA repair gene hyperexpression is linked to lack of tumor immune infiltration. J Immunother Cancer. 2022 06; 10(6).
Score: 0.024
-
Antibody and T cell responses to COVID-19 vaccination in patients receiving anticancer therapies. J Immunother Cancer. 2022 06; 10(6).
Score: 0.024
-
Dietary modulation of the gut microbiome as an immunoregulatory intervention. Cancer Cell. 2022 03 14; 40(3):246-248.
Score: 0.024
-
Immune cell and tumor cell-derived CXCL10 is indicative of immunotherapy response in metastatic melanoma. J Immunother Cancer. 2021 09; 9(9).
Score: 0.023
-
Cancer and the Microbiome-Influence of the Commensal Microbiota on Cancer, Immune Responses, and Immunotherapy. Gastroenterology. 2021 01; 160(2):600-613.
Score: 0.022
-
Immunotherapy with a sting. Science. 2020 08 21; 369(6506):921-922.
Score: 0.021
-
cDC1 dysregulation in cancer: An opportunity for intervention. J Exp Med. 2020 08 03; 217(8).
Score: 0.021
-
Strategies to overcome resistance to PD-1 inhibitors. Clin Adv Hematol Oncol. 2020 May; 18(5):270-272.
Score: 0.021
-
A case of dual-mechanism immune-related anaemia in a patient with metastatic melanoma treated with nivolumab and ipilimumab. J Immunother Cancer. 2020 03; 8(1).
Score: 0.021
-
Tumor heterogeneity and clonal cooperation influence the immune selection of IFN-?-signaling mutant cancer cells. Nat Commun. 2020 01 30; 11(1):602.
Score: 0.021
-
PAK4 as a cancer immune-evasion target. Nat Cancer. 2020 01; 1(1):18-19.
Score: 0.020
-
Secondary resistance to immunotherapy associated with ß-catenin pathway activation or PTEN loss in metastatic melanoma. J Immunother Cancer. 2019 11 08; 7(1):295.
Score: 0.020
-
STING pathway agonism as a cancer therapeutic. Immunol Rev. 2019 07; 290(1):24-38.
Score: 0.020
-
Exploring the emerging role of the microbiome in cancer immunotherapy. J Immunother Cancer. 2019 04 17; 7(1):108.
Score: 0.019
-
WNT/ß-catenin Pathway Activation Correlates with Immune Exclusion across Human Cancers. Clin Cancer Res. 2019 May 15; 25(10):3074-3083.
Score: 0.019
-
Severe hemophagocytic lymphohistiocytosis in a melanoma patient treated with ipilimumab + nivolumab. J Immunother Cancer. 2018 07 16; 6(1):73.
Score: 0.018
-
Fast Forward - Neoadjuvant Cancer Immunotherapy. N Engl J Med. 2018 05 24; 378(21):2034-2035.
Score: 0.018
-
Back from the dead: TIL apoptosis in cancer immune evasion. Br J Cancer. 2018 02 06; 118(3):309-311.
Score: 0.018
-
Impact of oncogenic pathways on evasion of antitumour immune responses. Nat Rev Cancer. 2018 03; 18(3):139-147.
Score: 0.018
-
The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. Science. 2018 01 05; 359(6371):104-108.
Score: 0.018
-
Intratumoral CD8+ T-cell Apoptosis Is a Major Component of T-cell Dysfunction and Impedes Antitumor Immunity. Cancer Immunol Res. 2018 01; 6(1):14-24.
Score: 0.018
-
The Microbiota: A New Variable Impacting Cancer Treatment Outcomes. Clin Cancer Res. 2017 07 01; 23(13):3229-3231.
Score: 0.017
-
First-in-Human Phase I Study of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase-1 Epacadostat (INCB024360) in Patients with Advanced Solid Malignancies. Clin Cancer Res. 2017 07 01; 23(13):3269-3276.
Score: 0.017
-
Cancer Immunotherapy Targets Based on Understanding the T Cell-Inflamed Versus Non-T Cell-Inflamed Tumor Microenvironment. Adv Exp Med Biol. 2017; 1036:19-31.
Score: 0.017
-
Innate immune signaling and regulation in cancer immunotherapy. Cell Res. 2017 Jan; 27(1):96-108.
Score: 0.017
-
Density of immunogenic antigens does not explain the presence or absence of the T-cell-inflamed tumor microenvironment in melanoma. Proc Natl Acad Sci U S A. 2016 11 29; 113(48):E7759-E7768.
Score: 0.016
-
The host STING pathway at the interface of cancer and immunity. J Clin Invest. 2016 07 01; 126(7):2404-11.
Score: 0.016
-
NK Cells Restrain Spontaneous Antitumor CD8+ T Cell Priming through PD-1/PD-L1 Interactions with Dendritic Cells. J Immunol. 2016 08 01; 197(3):953-61.
Score: 0.016
-
Manipulating the microbiome to improve the efficacy of immunotherapy. Clin Adv Hematol Oncol. 2016 Jun; 14(6):424-6.
Score: 0.016
-
Molecular Drivers of the Non-T-cell-Inflamed Tumor Microenvironment in Urothelial Bladder Cancer. Cancer Immunol Res. 2016 07; 4(7):563-8.
Score: 0.016
-
Germ Warfare. Sci Am. 2016 Apr; 314(4):50.
Score: 0.016
-
Tumor and Host Factors Controlling Antitumor Immunity and Efficacy of Cancer Immunotherapy. Adv Immunol. 2016; 130:75-93.
Score: 0.016
-
Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science. 2015 Nov 27; 350(6264):1084-9.
Score: 0.015
-
Molecular Pathways: Targeting the Stimulator of Interferon Genes (STING) in the Immunotherapy of Cancer. Clin Cancer Res. 2015 Nov 01; 21(21):4774-9.
Score: 0.015
-
Endogenous and pharmacologic targeting of the STING pathway in cancer immunotherapy. Cytokine. 2016 Jan; 77:245-7.
Score: 0.015
-
The Next Hurdle in Cancer Immunotherapy: Overcoming the Non-T-Cell-Inflamed Tumor Microenvironment. Semin Oncol. 2015 Aug; 42(4):663-71.
Score: 0.015
-
Melanoma-intrinsic ß-catenin signalling prevents anti-tumour immunity. Nature. 2015 Jul 09; 523(7559):231-5.
Score: 0.015
-
Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity. Cell Rep. 2015 May 19; 11(7):1018-30.
Score: 0.015
-
The STING pathway and the T cell-inflamed tumor microenvironment. Trends Immunol. 2015 Apr; 36(4):250-6.
Score: 0.015
-
Innate immune recognition of cancer. Annu Rev Immunol. 2015; 33:445-74.
Score: 0.015
-
New perspectives on type I IFNs in cancer. Cytokine Growth Factor Rev. 2015 Apr; 26(2):175-8.
Score: 0.014
-
Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol. 2013 Oct; 14(10):1014-22.
Score: 0.013
-
Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Sci Transl Med. 2013 Aug 28; 5(200):200ra116.
Score: 0.013
-
Cancer immunotherapy. Curr Opin Immunol. 2013 Apr; 25(2):259-60.
Score: 0.013
-
Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment. Curr Opin Immunol. 2013 Apr; 25(2):268-76.
Score: 0.013
-
Phase II study of the farnesyltransferase inhibitor R115777 in advanced melanoma (CALGB 500104). J Transl Med. 2012 Dec 10; 10:246.
Score: 0.013
-
Phase II study of the Src kinase inhibitor saracatinib (AZD0530) in metastatic melanoma. Invest New Drugs. 2013 Jun; 31(3):769-73.
Score: 0.012
-
Transcriptional regulator early growth response gene 2 (Egr2) is required for T cell anergy in vitro and in vivo. J Exp Med. 2012 Nov 19; 209(12):2157-63.
Score: 0.012
-
Type I interferon response and innate immune sensing of cancer. Trends Immunol. 2013 Feb; 34(2):67-73.
Score: 0.012
-
Innate immune sensing of cancer: clues from an identified role for type I IFNs. Cancer Immunol Immunother. 2012 Aug; 61(8):1343-7.
Score: 0.012
-
Cancer immunotherapy. Mol Oncol. 2012 Apr; 6(2):242-50.
Score: 0.012
-
Harnessing the immune response. Clin Adv Hematol Oncol. 2012 Jan; 10(1):46-8.
Score: 0.012
-
Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8{alpha}+ dendritic cells. J Exp Med. 2011 Sep 26; 208(10):2005-16.
Score: 0.012
-
Molecular profiling of melanoma and the evolution of patient-specific therapy. Semin Oncol. 2011 Apr; 38(2):236-42.
Score: 0.011
-
Molecular profiling to identify relevant immune resistance mechanisms in the tumor microenvironment. Curr Opin Immunol. 2011 Apr; 23(2):286-92.
Score: 0.011
-
Clinical development of mAbs to block the PD1 pathway as an immunotherapy for cancer. Curr Opin Investig Drugs. 2010 Dec; 11(12):1354-9.
Score: 0.011
-
Improved melanoma survival at last! Ipilimumab and a paradigm shift for immunotherapy. Pigment Cell Melanoma Res. 2010 Oct; 23(5):580-1.
Score: 0.011
-
Gene signature in melanoma associated with clinical activity: a potential clue to unlock cancer immunotherapy. Cancer J. 2010 Jul-Aug; 16(4):399-403.
Score: 0.011
-
A phase II study of oxaliplatin, docetaxel, and GM-CSF in patients with previously treated advanced melanoma. Cancer Chemother Pharmacol. 2010 Feb; 65(3):509-14.
Score: 0.010
-
Costimulatory and coinhibitory receptors in anti-tumor immunity. Immunol Rev. 2009 May; 229(1):126-44.
Score: 0.010
-
Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment. Cancer Res. 2009 Apr 01; 69(7):3077-85.
Score: 0.010
-
Emerging strategies in regulatory T-cell immunotherapies. Clin Adv Hematol Oncol. 2009 Jan; 7(1):1-10; quiz 11-2.
Score: 0.010
-
Immune-mediated red cell aplasia after anti-CTLA-4 immunotherapy for metastatic melanoma. Cancer Immunol Immunother. 2009 Aug; 58(8):1351-3.
Score: 0.010
-
Melanoma presenting as circulating tumor cells associated with failed angiogenesis. Melanoma Res. 2008 Aug; 18(4):289-94.
Score: 0.009
-
Molecular regulation of T-cell anergy. EMBO Rep. 2008 Jan; 9(1):50-5.
Score: 0.009
-
Failure at the effector phase: immune barriers at the level of the melanoma tumor microenvironment. Clin Cancer Res. 2007 Sep 15; 13(18 Pt 1):5256-61.
Score: 0.009
-
The expanding universe of regulatory T cell subsets in cancer. Immunity. 2007 Aug; 27(2):185-7.
Score: 0.009
-
Farnesyltransferase inhibitors inhibit T-cell cytokine production at the posttranscriptional level. Blood. 2007 Sep 15; 110(6):1982-8.
Score: 0.009
-
On the TRAIL toward death receptor-based cancer therapeutics. J Clin Oncol. 2007 Apr 10; 25(11):1305-7.
Score: 0.008
-
Immune resistance orchestrated by the tumor microenvironment. Immunol Rev. 2006 Oct; 213:131-45.
Score: 0.008
-
Induction of cytotoxic granules in human memory CD8+ T cell subsets requires cell cycle progression. J Immunol. 2006 Aug 01; 177(3):1981-7.
Score: 0.008
-
Immune suppression in the tumor microenvironment. J Immunother. 2006 May-Jun; 29(3):233-40.
Score: 0.008
-
Identifying and overcoming immune resistance mechanisms in the melanoma tumor microenvironment. Clin Cancer Res. 2006 Apr 01; 12(7 Pt 2):2326s-2330s.
Score: 0.008
-
Tumor progression despite massive influx of activated CD8(+) T cells in a patient with malignant melanoma ascites. Cancer Immunol Immunother. 2006 Oct; 55(10):1185-97.
Score: 0.008
-
Phase II trial of the O6-alkylguanine DNA alkyltransferase inhibitor O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea in advanced melanoma. Clin Cancer Res. 2005 Nov 01; 11(21):7861-5.
Score: 0.008
-
Randomized phase 2 study to assess the role of single-agent nivolumab to maintain remission in acute myeloid leukemia. Blood Adv. 2025 May 13; 9(9):2144-2152.
Score: 0.007
-
Lymphoma-infiltrating immune cells. N Engl J Med. 2005 Feb 17; 352(7):724-5; author reply 724-5.
Score: 0.007
-
Peripheral survival of naïve CD8+ T cells. Apoptosis. 2005 Jan; 10(1):5-11.
Score: 0.007
-
Metabolic mechanisms of tumor resistance to T cell effector function. Immunol Res. 2005; 31(2):107-18.
Score: 0.007
-
Targeting molecular pathways to control immune checkpoint inhibitor toxicities. Trends Immunol. 2025 Jan; 46(1):61-73.
Score: 0.007
-
Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours. Nature. 2025 Jan; 637(8048):1218-1227.
Score: 0.007
-
Dose-ranging pharmacodynamic study of tipifarnib (R115777) in patients with relapsed and refractory hematologic malignancies. J Clin Oncol. 2004 Dec 01; 22(23):4816-22.
Score: 0.007
-
Overcoming immune resistance in the tumor microenvironment by blockade of indoleamine 2,3-dioxygenase and programmed death ligand 1. Curr Opin Investig Drugs. 2004 Dec; 5(12):1279-83.
Score: 0.007
-
Depletion of normal B cells with rituximab as an adjunct to IL-2 therapy for renal cell carcinoma and melanoma. Ann Oncol. 2004 Jul; 15(7):1109-14.
Score: 0.007
-
Phase II study of the Flk-1 tyrosine kinase inhibitor SU5416 in advanced melanoma. Clin Cancer Res. 2004 Jun 15; 10(12 Pt 1):4048-54.
Score: 0.007
-
Immunotherapy-activated T cells recruit and skew late-stage activated M1-like macrophages that are critical for therapeutic efficacy. Cancer Cell. 2024 Jun 10; 42(6):1032-1050.e10.
Score: 0.007
-
Clinical responses following nonmyeloablative allogeneic stem cell transplantation for renal cell carcinoma are associated with expansion of CD8+ IFN-gamma-producing T cells. Bone Marrow Transplant. 2004 Mar; 33(5):491-7.
Score: 0.007
-
Update on vaccines for solid tumors. Clin Adv Hematol Oncol. 2004 Mar; 2(3):158-9.
Score: 0.007
-
Temozolomide for melanoma: new toxicities and new opportunities. J Clin Oncol. 2004 Feb 15; 22(4):580-1.
Score: 0.007
-
Negative regulation of T-cell function by PD-1. Crit Rev Immunol. 2004; 24(4):229-37.
Score: 0.007
-
Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 1st-3rd, 2022-Naples, Italy). J Transl Med. 2023 07 28; 21(1):508.
Score: 0.007
-
Disparate functions of immature and mature human myeloid dendritic cells: implications for dendritic cell-based vaccines. J Leukoc Biol. 2003 Jul; 74(1):69-80.
Score: 0.007
-
Immunization with Melan-A peptide-pulsed peripheral blood mononuclear cells plus recombinant human interleukin-12 induces clinical activity and T-cell responses in advanced melanoma. J Clin Oncol. 2003 Jun 15; 21(12):2342-8.
Score: 0.007
-
Phase 1 dose-escalation study of SEA-CD40: a non-fucosylated CD40 agonist, in advanced solid tumors and lymphomas. J Immunother Cancer. 2023 06; 11(6).
Score: 0.006
-
Germline immunomodulatory expression quantitative trait loci (ieQTLs) associated with immune-related toxicity from checkpoint inhibition. Eur J Cancer. 2023 08; 189:112923.
Score: 0.006
-
Association Between Rheumatic Autoantibodies and Immune-Related Adverse Events. Oncologist. 2023 05 08; 28(5):440-448.
Score: 0.006
-
Highly aneuploid non-small cell lung cancer shows enhanced responsiveness to concurrent radiation and immune checkpoint blockade. Nat Cancer. 2022 12; 3(12):1498-1512.
Score: 0.006
-
Proceedings From the ASCO/College of American Pathologists Immune Checkpoint Inhibitor Predictive Biomarker Summit. JCO Precis Oncol. 2022 11; 6:e2200454.
Score: 0.006
-
Severe COVID-19 induces autoantibodies against angiotensin II that correlate with blood pressure dysregulation and disease severity. Sci Adv. 2022 10 07; 8(40):eabn3777.
Score: 0.006
-
Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 2nd - 4th, 2021, Italy). J Transl Med. 2022 09 04; 20(1):391.
Score: 0.006
-
Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma. J Clin Oncol. 2023 01 20; 41(3):528-540.
Score: 0.006
-
Integrating IL-12 into therapeutic cancer vaccines. Cancer Chemother Biol Response Modif. 2002; 20:343-9.
Score: 0.006
-
Immunogenomic determinants of tumor microenvironment correlate with superior survival in high-risk neuroblastoma. J Immunother Cancer. 2021 07; 9(7).
Score: 0.006
-
Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 3rd-5th, 2020, Italy). J Transl Med. 2021 06 30; 19(1):278.
Score: 0.006
-
Cost-Effectiveness Analysis of Adjuvant Therapy for BRAF-Mutant Resected Stage III Melanoma in Medicare Patients. Ann Surg Oncol. 2021 Dec; 28(13):9039-9047.
Score: 0.006
-
Sensitive detection and quantification of SARS-CoV-2 in saliva. Sci Rep. 2021 06 14; 11(1):12425.
Score: 0.006
-
Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in Melanoma. J Clin Oncol. 2021 08 20; 39(24):2647-2655.
Score: 0.006
-
The p815 mastocytoma tumor model. Curr Protoc Immunol. 2001 May; Chapter 20:Unit 20.4.
Score: 0.006
-
Immunization of HLA-A2+ melanoma patients with MAGE-3 or MelanA peptide-pulsed autologous peripheral blood mononuclear cells plus recombinant human interleukin 12. Clin Cancer Res. 2001 Mar; 7(3 Suppl):895s-901s.
Score: 0.006
-
Novel response to neoadjuvant anti-PD1 therapy for a patient with retrocaval melanotic schwannoma. Melanoma Res. 2021 02 01; 31(1):92-97.
Score: 0.006
-
COVIDOSE: A Phase II Clinical Trial of Low-Dose Tocilizumab in the Treatment of Noncritical COVID-19 Pneumonia. Clin Pharmacol Ther. 2021 03; 109(3):688-696.
Score: 0.005
-
Improved Survival Associated with Local Tumor Response Following Multisite Radiotherapy and Pembrolizumab: Secondary Analysis of a Phase I Trial. Clin Cancer Res. 2020 12 15; 26(24):6437-6444.
Score: 0.005
-
Perspectives in melanoma: meeting report from the "Melanoma Bridge" (December 5th-7th, 2019, Naples, Italy). J Transl Med. 2020 09 07; 18(1):346.
Score: 0.005
-
Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19. J Immunother Cancer. 2020 04; 8(1).
Score: 0.005
-
Monitoring specific T-cell responses to melanoma vaccines: ELISPOT, tetramers, and beyond. Clin Diagn Lab Immunol. 2000 Mar; 7(2):141-4.
Score: 0.005
-
ACCELERATE and European Medicines Agency Paediatric Strategy Forum for medicinal product development of checkpoint inhibitors for use in combination therapy in paediatric patients. Eur J Cancer. 2020 03; 127:52-66.
Score: 0.005
-
Biochemical analysis of activated T lymphocytes. Protein phosphorylation and Ras, ERK, and JNK activation. Methods Mol Biol. 2000; 134:307-17.
Score: 0.005
-
Extended 5-Year Follow-up Results of a Phase Ib Study (BRIM7) of Vemurafenib and Cobimetinib in BRAF-Mutant Melanoma. Clin Cancer Res. 2020 01 01; 26(1):46-53.
Score: 0.005
-
Polymyositis with respiratory muscle weakness requiring mechanical ventilation in a patient with metastatic thymoma treated with octreotide. Ann Oncol. 1999 Aug; 10(8):973-9.
Score: 0.005
-
Perspectives in melanoma: meeting report from the Melanoma Bridge (November 29th-1 December 1st, 2018, Naples, Italy). J Transl Med. 2019 07 22; 17(1):234.
Score: 0.005
-
Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study. Lancet Oncol. 2019 08; 20(8):1083-1097.
Score: 0.005
-
Major pathologic response on biopsy (MPRbx) in patients with advanced melanoma treated with anti-PD-1: evidence for an early, on-therapy biomarker of response. Ann Oncol. 2019 04 01; 30(4):589-596.
Score: 0.005
-
Phase 1/2 study of epacadostat in combination with ipilimumab in patients with unresectable or metastatic melanoma. J Immunother Cancer. 2019 03 20; 7(1):80.
Score: 0.005
-
Brain Tumor Microenvironment and Host State: Implications for Immunotherapy. Clin Cancer Res. 2019 07 15; 25(14):4202-4210.
Score: 0.005
-
Improved efficacy of dendritic cell vaccines and successful immunization with tumor antigen peptide-pulsed peripheral blood mononuclear cells by coadministration of recombinant murine interleukin-12. Int J Cancer. 1999 Jan 18; 80(2):324-33.
Score: 0.005
-
The immune system as anti-tumor sentinel: molecular requirements for an anti-tumor immune response. Crit Rev Oncog. 1999; 10(3):247-60.
Score: 0.005
-
Distinct Graft-Specific TCR Avidity Profiles during Acute Rejection and Tolerance. Cell Rep. 2018 08 21; 24(8):2112-2126.
Score: 0.005
-
Improving Efficacy and Safety of Agonistic Anti-CD40 Antibody Through Extracellular Matrix Affinity. Mol Cancer Ther. 2018 11; 17(11):2399-2411.
Score: 0.005
-
Perspectives in melanoma: Meeting report from the Melanoma Bridge (30 November-2 December, 2017, Naples, Italy). J Transl Med. 2018 07 21; 16(1):207.
Score: 0.005
-
A pharmacodynamic study of sirolimus and metformin in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2018 08; 82(2):309-317.
Score: 0.005
-
An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0. J Immunother Cancer. 2018 05 30; 6(1):44.
Score: 0.005
-
Pseudoprogression manifesting as recurrent ascites with anti-PD-1 immunotherapy in urothelial bladder cancer. J Immunother Cancer. 2018 04 04; 6(1):24.
Score: 0.005
-
The microbiome in cancer immunotherapy: Diagnostic tools and therapeutic strategies. Science. 2018 03 23; 359(6382):1366-1370.
Score: 0.005
-
Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors. J Clin Oncol. 2018 06 01; 36(16):1611-1618.
Score: 0.004
-
Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab. Cell. 2017 Nov 02; 171(4):934-949.e16.
Score: 0.004
-
Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy. Cell. 2017 Sep 07; 170(6):1109-1119.e10.
Score: 0.004
-
Safety and efficacy of the antiganglioside GD3 antibody ecromeximab (KW2871) combined with high-dose interferon-a2b in patients with metastatic melanoma. Melanoma Res. 2017 08; 27(4):342-350.
Score: 0.004
-
Stem cell-like transcriptional reprogramming mediates metastatic resistance to mTOR inhibition. Oncogene. 2017 05 11; 36(19):2737-2749.
Score: 0.004
-
Relationship between physician-adjudicated adverse events and patient-reported health-related quality of life in a phase II clinical trial (NCT01143402) of patients with metastatic uveal melanoma. J Cancer Res Clin Oncol. 2017 Mar; 143(3):439-445.
Score: 0.004
-
Immunotherapy of head and neck cancer: Emerging clinical trials from a National Cancer Institute Head and Neck Cancer Steering Committee Planning Meeting. Cancer. 2017 Apr 01; 123(7):1259-1271.
Score: 0.004
-
Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015. J Transl Med. 2016 11 15; 14(1):313.
Score: 0.004
-
Lymphatic vessels regulate immune microenvironments in human and murine melanoma. J Clin Invest. 2016 09 01; 126(9):3389-402.
Score: 0.004
-
MYC - a thorn in the side of cancer immunity. Cell Res. 2016 06; 26(6):639-40.
Score: 0.004
-
Cutting Edge: Engineering Active IKKß in T Cells Drives Tumor Rejection. J Immunol. 2016 Apr 01; 196(7):2933-8.
Score: 0.004
-
A phase II study of cediranib, an oral VEGF inhibitor, in previously untreated patients with metastatic or recurrent malignant melanoma. Invest New Drugs. 2016 Apr; 34(2):231-5.
Score: 0.004
-
Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy. Cancer Discov. 2016 Feb; 6(2):202-16.
Score: 0.004
-
Future perspectives in melanoma research: meeting report from the "Melanoma Bridge": Napoli, December 3rd-6th 2014. J Transl Med. 2015 Nov 30; 13:374.
Score: 0.004
-
Rational development of tumour antigen-specific immunization in melanoma. Ther Immunol. 1995 Aug; 2(4):211-25.
Score: 0.004
-
Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition. Clin Cancer Res. 2015 May 15; 21(10):2289-96.
Score: 0.004
-
Metabolic response by FDG-PET to imatinib correlates with exon 11 KIT mutation and predicts outcome in patients with mucosal melanoma. Cancer Imaging. 2014 Nov 12; 14:30.
Score: 0.004
-
Future perspectives in melanoma research: meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013. J Transl Med. 2014 Oct 28; 12:277.
Score: 0.004
-
Phase 2 study of RO4929097, a gamma-secretase inhibitor, in metastatic melanoma: SWOG 0933. Cancer. 2015 Feb 01; 121(3):432-440.
Score: 0.004
-
Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study. Lancet Oncol. 2014 Aug; 15(9):954-65.
Score: 0.004
-
Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial. JAMA. 2014 Jun 18; 311(23):2397-405.
Score: 0.003
-
"Anergy" of TH0 helper T lymphocytes induces downregulation of TH1 characteristics and a transition to a TH2-like phenotype. J Exp Med. 1994 Feb 01; 179(2):481-91.
Score: 0.003
-
The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma. Nat Rev Clin Oncol. 2013 10; 10(10):588-98.
Score: 0.003
-
Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. J Clin Oncol. 2013 Sep 10; 31(26):3182-90.
Score: 0.003
-
Future perspectives in melanoma research. Meeting report from the "Melanoma Bridge. Napoli, December 2nd-4th 2012". J Transl Med. 2013 Jun 03; 11:137.
Score: 0.003
-
Cancer classification using the Immunoscore: a worldwide task force. J Transl Med. 2012 Oct 03; 10:205.
Score: 0.003
-
Phase I studies of sirolimus alone or in combination with pharmacokinetic modulators in advanced cancer patients. Clin Cancer Res. 2012 Sep 01; 18(17):4785-93.
Score: 0.003
-
Future perspectives in melanoma research. Meeting report from the "Melanoma research: a bridge from Naples to the World. Napoli, December 5th-6th 2011". J Transl Med. 2012 Jul 04; 10:83.
Score: 0.003
-
Workshop on immunotherapy combinations. Society for Immunotherapy of Cancer annual meeting Bethesda, November 3, 2011. J Transl Med. 2012 May 28; 10:108.
Score: 0.003
-
Ocular melanoma metastasis to the cervical spine. J Clin Neurosci. 2012 Apr; 19(4):610-1.
Score: 0.003
-
The immune score as a new possible approach for the classification of cancer. J Transl Med. 2012 Jan 03; 10:1.
Score: 0.003
-
Defining the critical hurdles in cancer immunotherapy. J Transl Med. 2011 Dec 14; 9:214.
Score: 0.003
-
SITC/iSBTc Cancer Immunotherapy Biomarkers Resource Document: online resources and useful tools - a compass in the land of biomarker discovery. J Transl Med. 2011 Sep 19; 9:155.
Score: 0.003
-
Review of the 25th annual scientific meeting of the International Society for Biological Therapy of Cancer. J Transl Med. 2011 May 12; 9:60.
Score: 0.003
-
Phase II study of immunomodulation with granulocyte-macrophage colony-stimulating factor, interleukin-2, and rituximab following autologous stem cell transplant in patients with relapsed or refractory lymphomas. Leuk Lymphoma. 2010 Jul; 51(7):1241-50.
Score: 0.003
-
Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study. Ann Oncol. 2010 Aug; 21(8):1712-1717.
Score: 0.003
-
A designer ligand specific for Kv1.3 channels from a scorpion neurotoxin-based library. Proc Natl Acad Sci U S A. 2009 Dec 29; 106(52):22211-6.
Score: 0.003
-
Regulation of T-cell activation: differences among T-cell subsets. Immunol Rev. 1989 Oct; 111:79-110.
Score: 0.003
-
PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model. Blood. 2009 Aug 20; 114(8):1545-52.
Score: 0.002
-
The HLA-A2-restricted PSMA peptide LLHETDSAV is poorly immunogenic in patients with metastatic prostate cancer. Prostate. 2009 Feb 01; 69(2):142-8.
Score: 0.002
-
Phase I/II trial of tremelimumab in patients with metastatic melanoma. J Clin Oncol. 2009 Mar 01; 27(7):1075-81.
Score: 0.002
-
Report on the ISBTC mini-symposium on biologic effects of targeted therapeutics. J Immunother. 2007 Sep; 30(6):577-90.
Score: 0.002
-
Targeting the primary tumor to generate CTL for the effective eradication of spontaneous metastases. J Immunol. 2007 Aug 01; 179(3):1960-8.
Score: 0.002
-
Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro. Int J Cancer. 2006 Jul 15; 119(2):317-27.
Score: 0.002
-
Production of TH1 and TH2 cell lines and clones. Curr Protoc Immunol. 2006 May; Chapter 3:3.13.1-3.13.15.
Score: 0.002
-
Innovations and challenges in melanoma: summary statement from the first Cambridge conference. Clin Cancer Res. 2006 Apr 01; 12(7 Pt 2):2291s-2296s.
Score: 0.002
-
A randomized phase II trial of interleukin-2 in combination with four different doses of bryostatin-1 in patients with renal cell carcinoma. Invest New Drugs. 2006 Mar; 24(2):141-9.
Score: 0.002
-
An adenoviral vector for probing promoter activity in primary immune cells. J Immunol Methods. 2006 Apr 20; 311(1-2):19-30.
Score: 0.002
-
Phase 2 study of the g209-2M melanoma peptide vaccine and low-dose interleukin-2 in advanced melanoma: Cancer and Leukemia Group B 509901. J Immunother. 2006 Jan-Feb; 29(1):95-101.
Score: 0.002
-
CCI-779 in metastatic melanoma: a phase II trial of the California Cancer Consortium. Cancer. 2005 Sep 01; 104(5):1045-8.
Score: 0.002
-
Long-term follow-up of nonmyeloablative allogeneic stem cell transplantation for renal cell carcinoma: The University of Chicago Experience. Bone Marrow Transplant. 2005 Feb; 35(3):253-60.
Score: 0.002
-
Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy. Cancer Immunol Immunother. 2005 Apr; 54(4):307-14.
Score: 0.002
-
Semiquantitative analysis of dynamic contrast enhanced MRI in cancer patients: Variability and changes in tumor tissue over time. J Magn Reson Imaging. 2004 Jul; 20(1):122-8.
Score: 0.002
-
A phase II study of bryostatin-1 and paclitaxel in patients with advanced non-small cell lung cancer. Lung Cancer. 2003 Feb; 39(2):191-6.
Score: 0.002
-
Flt-3 ligand and sequential FL/interleukin-2 in patients with metastatic renal carcinoma: clinical and biologic activity. J Immunother. 2002 May-Jun; 25(3):269-77.
Score: 0.002
-
Allogeneic stem-cell transplantation of renal cell cancer after nonmyeloablative chemotherapy: feasibility, engraftment, and clinical results. J Clin Oncol. 2002 Apr 15; 20(8):2017-24.
Score: 0.001
-
Antigen-specific blockade of T cells in vivo using dimeric MHC peptide. J Immunol. 2001 Sep 01; 167(5):2555-60.
Score: 0.001
-
Allogeneic peripheral blood stem cell transplantation for metastatic renal cell carcinoma. J Urol. 2001 Apr; 165(4):1208-9.
Score: 0.001
-
Transplantation and the CD28/CTLA4/B7 pathway. Transplant Proc. 2001 Feb-Mar; 33(1-2):209-11.
Score: 0.001
-
Transgenic expression of the coxsackie/adenovirus receptor enables adenoviral-mediated gene delivery in naive T cells. Proc Natl Acad Sci U S A. 2000 Dec 05; 97(25):13784-9.
Score: 0.001
-
Blockade of T cell activation using a surface-linked single-chain antibody to CTLA-4 (CD152). J Immunol. 2000 May 01; 164(9):4433-42.
Score: 0.001
-
B7.1 is a quantitatively stronger costimulus than B7.2 in the activation of naive CD8+ TCR-transgenic T cells. J Immunol. 1998 Nov 15; 161(10):5268-75.
Score: 0.001
-
Induction of a cytolytic T-cell response in mice with a recombinant adenovirus coding for tumor antigen P815A. Int J Cancer. 1996 Jul 17; 67(2):303-10.
Score: 0.001
-
From defined human tumor antigens to effective immunization? Immunol Today. 1995 Jul; 16(7):334-6.
Score: 0.001
-
A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3. Eur J Immunol. 1994 Dec; 24(12):3038-43.
Score: 0.001
-
[Use of valvular drainage of the pleural cavity in the treatment of spontaneous pneumothorax]. Pol Przegl Chir. 1972 Aug; 44(8):1373-7.
Score: 0.001
-
Nakahara memorial lecture. Regulation of T lymphocyte responses: interactions among receptors. Princess Takamatsu Symp. 1988; 19:15-27.
Score: 0.001
-
[2- and multistage surgical procedures on the intestines]. Pol Przegl Chir. 1967 Dec; 39(12):1277-80.
Score: 0.001
-
[Osteoid osteoma]. Pol Przegl Chir. 1962 Jul; 34:721-3.
Score: 0.000
-
[A case of effusion of chyle into the pleural and peritoneal cavity]. Pediatr Pol. 1962 Feb; 37:183-6.
Score: 0.000
-
[Perthes' syndrome after crushing of the thorax]. Pol Tyg Lek. 1961 Jan 16; 16:94-6.
Score: 0.000
-
[Case of foreign body in the brain]. Wiad Lek. 1979 Dec 15; 32(24):1777-9.
Score: 0.000
-
[Indications concerning the management of patients with artificial anus]. Pol Tyg Lek. 1959 Jun 29; 14:1212-4.
Score: 0.000